Bcl-2 family proteins are essential for platelet survival
The DOI matches its Crossref record; 31 of the 32 references it cites were found in a registry or an index.
Abstract
Platelets are relatively short-lived, anucleated cells that are essential for proper hemostasis. The regulation of platelet survival in the circulation remains poorly understood. The process of platelet activation and senescence in vivo is associated with processes similar to those observed during apoptosis in nucleated cells, including loss of mitochondrial membrane potential, caspase activation, phosphatidylserine (PS) externalization, and cell shrinkage. ABT-737, a potent antagonist of Bcl-2, Bcl-X(L), and Bcl-w, induces apoptosis in nucleated cells dependent on these proteins for survival. In vivo, ABT-737 induces a reduction of circulating platelets that is maintained during drug therapy, followed by recovery to normal levels within several days after treatment cessation. Whole body scintography utilizing ([111])Indium-labeled platelets in dogs shows that ABT-737-induced platelet clearance is primarily mediated by the liver. In vitro, ABT-737 treatment leads to activation of key apoptotic processes including cytochrome c release, caspase-3 activation, and PS externalization in isolated platelets. Despite these changes, ABT-737 is ineffective in promoting platelet activation as measured by granule release markers and platelet aggregation. Taken together, these data suggest that ABT-737 induces an apoptosis-like response in platelets that is distinct from platelet activation and results in enhanced clearance in vivo by the reticuloendothelial system.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, targeting BCL-XL with conventional inhibitors causes severe thrombocytopenia, limiting their clinical use [5–7].”
From BCL-XL PROTAC degrader DT2216 synergizes with sotorasib in preclinical models of KRASG12C-mutated cancers (2022) · cites this paper as [6]
In the citing paper
“a potential clinical limitation of BCL-XLi is the fact that these inhibitors can cause on-target, reversible thrombocytopenia (Zhang et al., 2007).”
From A Landscape of Therapeutic Cooperativity in KRAS Mutant Cancers Reveals Principles for Controlling Tumor Evolution (2017) · cites this paper as Zhang et al., 2007
Citations
Cites
An inhibitor of Bcl-2 family proteins induces regression of solid tumours
Oltersdorf, T., Elmore, S. W., Shoemaker, A. R., Armstrong, R. C., Augeri, D. J., Belli, B. A., Bruncko, M., Deckwerth, T. L., Dinges, J., Hajduk, P. J., et al. (2005) · Nature · doi:10.1038/nature03579 · Cited by 3,416 · cited 2×
“ABT-737 is a small molecule antagonist of the prosurvival Bcl-2 family proteins Bcl-XL, Bcl-2, and Bcl-w that induces apoptosis in tumor cells in a mitochondria-dependent fashion.(18) Treatment of ABT-737 in dogs leads to a rapid, dosedependent decrease in circulating platelets that return to baseline within 72-h post…”
BackgroundSelf-citationA receptor for phosphatidylserine-specific clearance of apoptotic cells
Fadok, V. A., Bratton, D. L., Rose, D. M., Pearson, A., Ezekewitz, R. A. B., & Henson, P. M. (2000) · Nature · doi:10.1038/35011084 · Cited by 1,491 · cited 1×
“PS externalization on cells has also been shown to signal the specific engulfment of these unwanted cells by phagocytes leading to clearance from the circulation .(9,15,25) Finally, the fact that the enantiomer negative control does not activate the apoptotic cascade at equivalent concentrations supports the notion th…”
BackgroundThe biogenesis of platelets from megakaryocyte proplatelets
Patel, S. R. (2005) · Journal of Clinical Investigation · doi:10.1172/jci26891 · Cited by 603 · cited 1×
“The similarities between platelet biogenesis from megakaryocytes and apoptosis include membrane blebbing, membrane condensation, DNA fragmentation, cell shrinkage, and ultimately the formation of apoptotic bodies.(5,6) The consequence of this apoptotic process is that each mature megakaryocyte fragments into thousands…”
BackgroundThe platelet release reaction: granules' constituents, secretion and functions
Rendu, F., & Brohard-Bohn, B. (2001) · Platelets · doi:10.1080/09537100120068170 · Cited by 599 · cited 4×
“Upon platelet activation, a series of granules are released that are essential for the full activation response.(21) To further investigate other direct effects of ABT-737 on platelet dynamics, isolated platelets were treated with ABT-737 and classical markers of granule release were monitored.”
BackgroundMethodInfluentialProgrammed cell death and Bcl-2 protection in the absence of a nucleus.
Jacobson, M. D., Burne, J. F., & Raff, M. C. (1994) · The EMBO Journal · doi:10.1002/j.1460-2075.1994.tb06459.x · Cited by 552 · cited 1×
“Previous studies have shown that apoptotic agents promote morphological changes in anucleated cytoplast that resemble characteristics of programmed cell death.(23,24) In platelets, the morphological changes of apoptosis closely resemble those of activation, including PS externalization, microparticle release (i.”
BackgroundMartin, S. J., Finucane, D. M., Amarante-Mendes, G. P., O'Brien, G. A., & Green, D. R. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.46.28753 · Cited by 372 · cited 1×
“Previous studies have shown that apoptotic agents promote morphological changes in anucleated cytoplast that resemble characteristics of programmed cell death.(23,24) In platelets, the morphological changes of apoptosis closely resemble those of activation, including PS externalization, microparticle release (i.”
BackgroundWolf, B. B., Goldstein, J. C., Stennicke, H. R., Beere, H., Amarante-Mendes, G. P., Salvesen, G. S., & Green, D. R. (1999) · Blood · doi:10.1182/blood.v94.5.1683 · Cited by 323
The role of the Bcl-2 protein family in cancer
Coultas, L., & Strasser, A. (2003) · Seminars in Cancer Biology · doi:10.1016/s1044-579x(02)00129-3 · Cited by 242 · cited 1×
“The process of apoptosis can be viewed as a cascade of events initiating from the accumulation of a death signal(s), release of apoptotic factors from the mitochondria, activation of initiator/effector caspases, ultimately leading to cell death.(16) Our studies demonstrate that ABT-737 initiates the apoptotic cascade…”
BackgroundA Simple Nonradioisotope Technic for the Determination of Platelet Life-Span
Stuart, M. J., Murphy, S., & Oski, F. A. (1975) · New England Journal of Medicine · doi:10.1056/nejm197506192922502 · Cited by 242 · cited 1×
“released into the circulation, platelets rapidly age with a halflife of 4–5 days.(7,8) As platelets age, they lose their ability to function and are subsequently removed from circulation.”
BackgroundRole of platelets in thrombosis and hemostasis
Packham, M. A. (1994) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/y94-043 · Cited by 215 · cited 2×
“Subsequent platelet activation, granule release, and aggregation are essential for the formation of a hemostatic plug that limits blood loss and stimulates repair.(2) There are several morphological changes associated with platelet activation that are reminiscent of nucleated cell apoptosis.”
Background
Cited by
Items 201–300 of 452
From Mitochondrial Biology to Magic Bullet: Navitoclax Disarms BCL-2 in Chronic Lymphocytic Leukemia
Walensky, L. D. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.37.9339 · Cited by 41
A Bcl-xL Timer Sets Platelet Life Span
Qi, B., & Hardwick, J. M. (2007) · Cell · doi:10.1016/j.cell.2007.03.002 · Cited by 41
“The small molecule ABT-737, designed to mimic the BH3 domain of proapoptotic Bcl-2 family proteins by inserting into the cleft on Bcl-xL, rapidly induced thrombocytopenia in mice (Mason et al., 2007) and in dogs (Zhang et al., 2007).”
BackgroundResultContact- and agonist-regulated microvesiculation of human platelets
Liu, X., Liu, L., Zaske, A. M., Zhou, Z., Fu, Y., Yang, X., Conyers, J. L., Li, M., Zhang, Y., Dong, J.-F., et al. (2013) · Thrombosis and Haemostasis · doi:10.1160/th12-11-0853 · Cited by 38
“The latter results from a disruption of the balance between Bcl survival and Bak apoptotic signals (12, 13, 18, 19), and may occur independently of platelet activation.”
BackgroundInhibition of Bcl-xL sensitizes cells to mitotic blockers, but not mitotic drivers
Bennett, A., Sloss, O., Topham, C. H., Nelson, L., Tighe, A., & Taylor, S. S. (2016) · Open Biology · doi:10.1098/rsob.160134 · Cited by 41
“Indeed, Bcl-xL is a molecular clock in platelets, defining their lifespan [64,65].”
P2Y12 protects platelets from apoptosis via PI3k‐dependent Bak/Bax inactivation
Zhang, S., Ye, J. H., Zhang, Y., Xu, X., Liu, J.-X., ZHANG, S. H., Kunapuli, S. P., & Ding, Z. (2012) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.12063 · Cited by 41
Hyperthermia induces platelet apoptosis and glycoprotein Ibα ectodomain shedding
Wang, Z., Shi, Q., Li, S., Du, J., Liu, J., & Dai, K. (2010) · Platelets · doi:10.3109/09537100903443949 · Cited by 36
“Up to now, most of the platelet apoptotic events appear to arise from the mitochondrial pathway, characterized by depolarization of mitochondrial inner transmembrane potential (D m), caspase-3 activation and verifications of the Bcl-2 family protein expression [11, 17, 18].”
BackgroundZoeller, J. J., Vagodny, A., Daniëls, V. W., Taneja, K. L., Tan, B. Y., DeRose, Y. S., Fujita, M., Welm, A. L., Letai, A. G., Leverson, J. D., et al. (2020) · Breast Cancer Research · doi:10.1186/s13058-020-01374-8 · Cited by 37
Weyland, M., Manero, F., Paillard, A., Gree, D. M., Viault, G., Jarnet, D., Meneï, P., Juin, P. P., Chourpa, I., Benoît, J., et al. (2010) · Journal of Controlled Release · doi:10.1016/j.jconrel.2010.11.032 · Cited by 36
“Although they are cell permeant and can easily reach intracellular targets, theymay also exert side effects as observed on platelet depletion with other Bcl-2 inhibitors [39].”
BackgroundStapled peptides as a new technology to investigate protein–protein interactions in human platelets
Iegre, J., Ahmed, N. S., Gaynord, J. S., Wu, Y., Herlihy, K. M., Tan, Y. S., Pires, M. E. L., Jha, R., Lau, Y. H., Sore, H. F., et al. (2018) · Chemical Science · doi:10.1039/c8sc00284c · Cited by 40
Tutumlu, G., Doğan, B., Avşar, T., Orhan, M. D., Calis, S., & Durdağı, S. (2020) · Frontiers in Chemistry · doi:10.3389/fchem.2020.00167 · Cited by 37
Non-Alloimmune Mechanisms of Thrombocytopenia and Refractoriness to Platelet Transfusion
Belizaire, R., & Makar, R. S. J. (2020) · Transfusion Medicine Reviews · doi:10.1016/j.tmrv.2020.09.002 · Cited by 38
“antiapoptotic pathways promotes platelet death and removal from the circulation [64-66].”
Khan, S., Cao, L., Wiegand, J., Zhang, P., Zajac-Kaye, M., Kaye, F. J., Zheng, G., & Zhou, D. (2024) · Cells · doi:10.3390/cells13060528 · Cited by 34
Johnson, L., Schubert, P., Tan, S. S. L., Devine, D. V., & Marks, D. C. (2015) · Transfusion · doi:10.1111/trf.13345 · Cited by 34
“mice(37) and increased clearance in dogs.(32) Further, human apoptotic PLTs undergo accelerated clearance by macrophages in vitro(38) and annexin V positivity is associated with reduced survival and clearance.”
BackgroundGoh, Y. C., Yap, C. T., Huang, B. H., Cronshaw, A. D., Leung, B. P. L., Lai, P. B. S., Hart, S. P., Dransfield, I., & Ross, J. A. (2010) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-010-0534-0 · Cited by 37
“Platelet senescence is also associated with loss of mitochondrial transmembrane potential and PtdSer exposure [36, 37].”
BackgroundA concise review of BCL-2 inhibition in acute myeloid leukemia
Yogarajah, M., & Stone, R. M. (2018) · Expert Review of Hematology · doi:10.1080/17474086.2018.1420474 · Cited by 34
“The stroma appeared to lower the expression of BCL-2 but increase expression of BCL-XL and BCLXS suggesting a switch in apoptosis-dependence from BCL-2 to BCL-XL.”
BackgroundInfluentialCan preclinical drug development help to predict adverse events in clinical trials?
Chi, L. H., Burrows, A. D., & Anderson, R. L. (2021) · Drug Discovery Today · doi:10.1016/j.drudis.2021.08.010 · Cited by 34
Garciaz, S., Saillard, C., Hicheri, Y., & Vey, N. (2021) · Cancers · doi:10.3390/cancers13225608 · Cited by 37
Schoenwaelder, S. M., & Jackson, S. P. (2012) · Blood · doi:10.1182/blood-2011-10-387399 · Cited by 34
Krishnan, S., Gaspari, M., Corte, A. D., Bianchi, P., Crescente, M., Cerletti, C., Torella, D., Indolfi, C., de Gaetano, G., Donati, M. B., et al. (2011) · Electrophoresis · doi:10.1002/elps.201000592 · Cited by 37
Puglisi, M., Molife, L. R., de Jonge, M. J., Khan, K. H., Doorn, L. V., Forster, M. D., Blanco, M., Gutierrez, M., Franklin, C., Busman, T., et al. (2021) · Future Oncology · doi:10.2217/fon-2021-0140 · Cited by 32
From Apoptosis to Necroptosis: The Death Wishes to Cancer
Meng, X., Dang, T., & Chai, J. (2021) · Cancer Control · doi:10.1177/10732748211066311 · Cited by 35
Fujii, T., & Matsuda, Y. (2023) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2023.2276873 · Cited by 35
“Turning to cancer treatment, Bcl-2 family proteins [59,60], cell survival and death regulators, have become key targets.”
BackgroundDevelopment of venetoclax for therapy of lymphoid malignancies
Zhu, H., & Almasan, A. (2017) · Drug Design Development and Therapy · doi:10.2147/dddt.s109325 · Cited by 34
“As BCL-xL is a key survival factor for platelets, 24 the patients administered navitoclax suffered from acute thrombocytopenia.”
BackgroundReilly, E. O., Dhami, S. P. S., Baev, D. V., Ortutay, C., McCormick, A., Morrell, R., Santocanale, C., Samali, A., Quinn, J., O'Dwyer, M. E., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-33982-y · Cited by 34
Judd, A. S., Bawa, B., Buck, W. R., Tao, Z., Li, Y., Mitten, M. J., Bruncko, M., Catron, N. D., Doherty, G. A., Durbin, K. R., et al. (2024) · Science Advances · doi:10.1126/sciadv.ado7120 · Cited by 32
“As predicted by preclinical data ( 10 ), systemic inhibition of BCL-X L with navitoclax induces a rapid, concentration-dependent decrease in circulating platelets.”
Self-citationNovel and emerging targeted-based cancer therapy agents and methods
Hojjat‐Farsangi, M. (2015) · Tumor Biology · doi:10.1007/s13277-015-3184-x · Cited by 31
“Bcl-XL is highly expressed on platelets, and navitoclax induced thrombocytopenia in treated patients [14].”
BackgroundStein, M. N., Goodin, S., Gounder, M., Gibbon, D. G., Moss, R. A., Portal, D. E., Lindquist, D., Zhao, Y., Takebe, N., Tan, A. R., et al. (2019) · Investigational New Drugs · doi:10.1007/s10637-019-00807-2 · Cited by 31
Reid, S., Johnson, L., Woodland, N., & Marks, D. C. (2012) · Transfusion · doi:10.1111/j.1537-2995.2011.03558.x · Cited by 31
“The intrinsic pathway of apoptosis is regulated through a balance between the proapoptotic and antiapoptotic members of the Bcl-2 family proteins.(17,25,26) It was hypothesized that the increase in apoptotic markers observed in PRT-treated PLTs was due to an increase in the expression and activation of proteins involv…”
BackgroundResultMicro-Economics of Apoptosis in Cancer: ncRNAs Modulation of BCL-2 Family Members
Villanova, L., Careccia, S., Maria, R. D., & Fiori, M. E. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19040958 · Cited by 32
“Unfortunately, the emergence of thrombocytopenia owing to BCL-XL targeting in platelets put a halt to its use in the clinic [98,99].”
BackgroundLien, L., Su, C., Hsu, W., Lu, W., Chung, C., Yen, T., Chiu, H., Sheu, J., & Lin, K. (2013) · Phytotherapy Research · doi:10.1002/ptr.4911 · Cited by 30
“Recently, several reports have shown that platelet apoptosis might be associated with lifespan of platelets (Mason et al., 2007; Zhang et al., 2007).”
BackgroundBH3‐only protein bid participates in the Bcl‐2 network in healthy liver cells†
Hikita, H., Takehara, T., Kodama, T., Shimizu, S., Hosui, A., Miyagi, T., Tatsumi, T., Ishida, H., Ohkawa, K., Li, W., et al. (2009) · Hepatology · doi:10.1002/hep.23207 · Cited by 31
Micha, D., Cummings, J., Shoemaker, A. R., Elmore, S., Foster, K., Greaves, M. J., Ward, T. H., Rosenberg, S. H., Dive, C., & Simpson, K. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0111 · Cited by 30
Self-citationFuentes, M., Araya‐Maturana, R., Palomo, I. F., & Fuentes, E. (2018) · Biochemical Pharmacology · doi:10.1016/j.bcp.2018.08.035 · Cited by 30
“both platelet function and senescence process [25].”
Zhang, Y., Gao, D., Yuan, Y., Zheng, R., Sun, M., Jia, S., & Liu, J. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24076554 · Cited by 32
“However, most reported senolytics are dependent on cell type and exhibit substantial cytotoxicities in vivo, including neutropenia and platelet deficiency [12], limiting their potential use for clinical purposes.”
BackgroundThe BH3-Mimetic ABT-737 Induces Mast Cell Apoptosis In Vitro and In Vivo: Potential for Therapeutics
Karlberg, M., Ekoff, M., Huang, D. C. S., Mustonen, P., Harvima, I. T., & Nilsson, G. P. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0903656 · Cited by 31
“However, other studies demonstrated that platelets and lymphocytes also exhibit sensitivity to ABT-737 (42, 43).”
BackgroundBae, O., Lim, K., Noh, J.-Y., Chung, S.-M., Kim, S., & Chung, J. (2009) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2008.12.020 · Cited by 29
Josefsson, E. C. (2022) · Thrombosis Research · doi:10.1016/j.thromres.2022.11.024 · Cited by 29
DeHelian, D., Gupta, S., Wu, J., Thorsheim, C. L., Estevez, B., Cooper, M., Litts, K., Lee‐Sundlov, M. M., Hoffmeister, K. M., Poncz, M., et al. (2020) · Blood · doi:10.1182/blood.2019003251 · Cited by 27
PROTACs are effective in addressing the platelet toxicity associated with BCL-XL inhibitors
Zhang, P., Zhang, X., Liu, X., Khan, S. U., Zhou, D., & Zheng, G. (2020) · Exploration of Targeted Anti-tumor Therapy · doi:10.37349/etat.2020.00017 · Cited by 28
“BCL-XL is an ideal protein for the proof-of-concept study of using PROTAC to overcome the on-target toxicity because thrombocytopenia is known on-target toxicity associated with BCL-XL inhibition in platelets [38, 39].”
BackgroundTargeting the apoptosis pathway to treat tumours of the paediatric nervous system
Fitzgerald, M.-C., O’Halloran, P. J., Connolly, N. M. C., & Murphy, B. M. (2022) · Cell Death and Disease · doi:10.1038/s41419-022-04900-y · Cited by 29
“However, in vivo ABT-737 treatment resulted in platelet apoptosis [61] due to the exquisite antiapoptotic dependence of platelets on BCL-XL [62], leading to reduced platelet and lymphocyte counts [60].”
BackgroundSingh, A., Jayanthan, A., Farran, A., Elwi, A. N., Kim, S.-W., Farran, P. R., & Narendran, A. (2011) · Leukemia Research · doi:10.1016/j.leukres.2011.06.035 · Cited by 32
Xie, S., Jiang, C., Wu, M. Y., Ye, Y., Wu, B., Sun, X., Lv, X., Chen, R., Yu, W., Sun, Q., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abn9061 · Cited by 26
Proteolysis targeting chimeras in non-small cell lung cancer
Hagopian, G. G., Grant, C., & Nagasaka, M. (2023) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2023.102561 · Cited by 27
Aspirin Delimits Platelet Life Span by Proteasomal Inhibition
Nayak, M. K., Dash, A., Singh, N. K., & Dash, D. (2014) · PLoS ONE · doi:10.1371/journal.pone.0105049 · Cited by 27
“The pro-apoptotic Bcl2 family protein Bax and Bax-specific mRNA are known to be abundantly expressed in platelets [54,55].”
BackgroundRegulation of platelet lifespan in the presence and absence of thrombopoietin signaling
Lebois, M., Dowling, M. R., Gangatirkar, P., Hodgkin, P. D., Kile, B. T., Alexander, W. S., & Josefsson, E. C. (2016) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.13397 · Cited by 28
Antileukemic efficacy of a potent artemisinin combined with sorafenib and venetoclax
Moses, B. S., McCullough, S., Fox, J. M., Mott, B. T., Bentzen, S. M., Kim, M.-J., Tyner, J. W., Lapidus, R. G., Emadi, A., Rudek, M. A., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2020003429 · Cited by 27
The Regulation of Platelet Life Span
Josefsson, E. C., Dowling, M. R., Lebois, M., & Kile, B. T. (2012) · Elsevier eBooks · doi:10.1016/b978-0-12-387837-3.00003-1 · Cited by 34
Mondal, N. K., Li, T., Chen, Z., Chen, H. H., Sorensen, E. N., Pham, S. M., Sobieski, M. A., Koenig, S. C., Slaughter, M. S., Griffith, B. P., et al. (2017) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-017-3021-1 · Cited by 26
“[35] showed that the induction of platelet apoptosis enhances its clearance in vivo by the reticuloendothelial system.”
Lu, R., Lin, Q., Chen, S., & Ye, X. (2020) · Translational Cancer Research · doi:10.21037/tcr.2020.01.64 · Cited by 24
“The mechanism of thrombocytopenia varies according to therapeutic regimens; for example, alkylating chemotherapeutic drugs mainly affect multipotent stem cells (21,22); cyclophosphamide mainly affects megakaryocyte progenitor cells (23); bortezomib causes thrombocytopenia by inhibiting nuclear transcription factor κB…”
BackgroundStamelos, V. A., Redman, C. W. E., & Richardson, A. (2012) · Journal of Molecular Signaling · doi:10.1186/1750-2187-7-12 · Cited by 30
“However, the lifespan of platelets is regulated by BCL-XL which consequently is shortened by ABT-737 [128,129].”
BackgroundCurrent challenges and novel treatment strategies in double hit lymphomas
Anderson, M. A., Tsui, A. E., Wall, M., Huang, D. C. S., & Roberts, A. W. (2015) · Therapeutic Advances in Hematology · doi:10.1177/2040620715608091 · Cited by 25
Erythrocyte and platelet proteomics in hematological disorders
Chakrabarti, A., Halder, S., & Karmakar, S. (2015) · PROTEOMICS - CLINICAL APPLICATIONS · doi:10.1002/prca.201500080 · Cited by 24
“The toxicity pathway identified in platelets highlights that platelet life span is governed by apoptotic mechanism and involves platelet shedding regulated by BCl-2 family [123].”
BackgroundMutlu, A., Gyulkhandanyan, A. V., Freedman, J. J., & Leytin, V. (2013) · British Journal of Haematology · doi:10.1111/bjh.12529 · Cited by 26
“…A, (ii) diluent buffer B, (iii) 1 U/ml thrombin, (iv) 30 lmol/ l ABT-737, and (v) 10 lmol/l A23187 (Leytin et al, 2000a,b, 2004a, 2006a, 2009; Zhang et al, 2007; Gyulkhandanyan et al, 2013); each treatment was performed in the presence of CaCl2 in a final concentration of 2 mmol/l (Leytin et…”
BackgroundMethodGyulkhandanyan, A. V., Mutlu, A., Allen, D. J., Freedman, J. J., & Leytin, V. (2013) · Thrombosis Research · doi:10.1016/j.thromres.2013.10.041 · Cited by 23
“In this case, platelet removal from the circulation takes place without participation of cell shrinkage and MP generation (i) by stimulation of different platelet caspases, such as caspases-9, -8 and -3 [13], which cleave a broad spectrum of vital cell proteins [33,34] and/or (ii) by a strong PS exposure on the surfac…”
BackgroundInfluentialCalmodulin antagonists induce platelet apoptosis
Wang, Z., Li, S., Shi, Q., Yan, R., Liu, G.-L., & Dai, K. (2010) · Thrombosis Research · doi:10.1016/j.thromres.2010.02.001 · Cited by 23
“Both weak and strong agonists induce depolarization of ΔΨm and caspase-3 activation in platelets [19,23,37,38].”
General Aspects of Thrombocytopenia, Platelet Transfusions, and Thrombopoietic Growth Factors
Kuter, D. J. (2019) · Elsevier eBooks · doi:10.1016/b978-0-323-46202-0.00007-8 · Cited by 23
Sharma, P., & Pollyea, D. A. (2018) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-018-0464-8 · Cited by 23
Long, Q., Li, L., Wang, H., Li, M., Wang, L., Zhou, M., Su, Q., Chen, T., & Wu, Y. (2018) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.14032 · Cited by 23
Delbridge, A. R. D., Aubrey, B. J., Hyland, C. D., Bernardini, J. P., Rago, L. D., Garnier, J., Lessène, G., Strasser, A., Alexander, W. S., & Grabow, S. (2017) · Cell Death and Disease · doi:10.1038/cddis.2017.304 · Cited by 22
Palominos, C., Fuentes-Retamal, S., Salazar, J. P., Guzmán‐Rivera, D., Correa, P., Mellado, M., Araya‐Maturana, R., & Urra, F. A. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.216965 · Cited by 21
Apoptotic Ablation of Platelets Reduces Atherosclerosis in Mice With Diabetes
Lee, M. K. S., Kraakman, M. J., Dragoljevic, D., Hanssen, N. M. J., Flynn, M., Al‐Sharea, A., Sreejit, G., Veiga, C. B., Cooney, O. D., Baig, F., et al. (2021) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.120.315369 · Cited by 21
Structure-Based Design of A-1293102, a Potent and Selective BCL-XL Inhibitor
Tao, Z., Wang, X., Chen, J., Ingram, J. P., Jin, S. S., Judge, R. A., Kovar, P. J., Park, C., Sun, C. C., Wakefield, B. D., et al. (2021) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.1c00162 · Cited by 23
Self-citationTargeting KRAS in pancreatic cancer: Emerging therapeutic strategies
Khan, S. U., Budamagunta, V., & Zhou, D. (2023) · Advances in cancer research · doi:10.1016/bs.acr.2023.02.004 · Cited by 23
Fernandez, E. G., Mai, W. X., Song, K., Bayley, N. A., Kim, J., Zhu, H., Pioso, M. S., Young, P., Andrasz, C. L., Cadet, D., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-54138-9 · Cited by 22
Gorombei, P., Guidez, F., Ganesan, S., Chiquet, M., Pellagatti, A., Goursaud, L., Tekin, N., Beurlet, S., Patel, S., Guerenne, L., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221910658 · Cited by 22
Therapeutic opportunities for counteracting apoptosis resistance in childhood leukaemia
Fulda, S. (2009) · British Journal of Haematology · doi:10.1111/j.1365-2141.2009.07603.x · Cited by 22
“The toxicities that were associated with ABT-263 treatment are considered to be mechanism-based, since the reduction in circulating platelet counts has been shown to be due to the critical role of Bcl-XL in platelet survival (Mason et al, 2007; Zhang et al, 2007; Wilson et al, 2008).”
BackgroundBusche, S., John, K., Wandrer, F., Vondran, F. W. R., Lehmann, U., Wedemeyer, H. H., Eßmann, F., Schulze‐Osthoff, K., & Bantel, H. (2021) · Cell Death and Disease · doi:10.1038/s41419-021-04020-z · Cited by 20
Selectivity mechanism of BCL-XL/2 inhibition through in silico investigation
Luan, J., Hu, B., Wang, S., Liu, H., Lu, S., Li, W., Sun, X., Shi, J., & Wang, J. (2022) · Physical Chemistry Chemical Physics · doi:10.1039/d2cp01755e · Cited by 19
Unleashing the biomimetic targeting potential of platelet-derived nanocarriers on atherosclerosis
Jan, N., Bostanudin, M. F., Moutraji, S. A., Kremesh, S., Kamal, Z., & Hanif, M. F. (2024) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2024.113979 · Cited by 19
Senescent cells in the brain and where to find them
Rachmian, N., & Krizhanovsky, V. (2022) · FEBS Journal · doi:10.1111/febs.16649 · Cited by 20
Apoptosis is one cause of thrombocytopenia in patients with high-altitude polycythemia
Wang, Z., Tenzing, N., Xu, Q., Liu, H., Ye, Y., Wen, Y., Wuren, T., & Cui, S. (2023) · Platelets · doi:10.1080/09537104.2022.2157381 · Cited by 19
“Specifically, binding of Bak/Bax to the mitochondrial membrane induces MMP depolarization and caspase-3 activation, which eventually result in platelet apoptosis [32–35].”
BackgroundPROTAC-loaded nanocapsules degrading BRD4 for radio-chemotherapy sensitization in glioblastoma
Guo, Y., Fang, M., Zhang, S., Zhou, Z., Tian, Z., You, H., Chen, Y., Zhou, J., Yang, X., Bi, Y., et al. (2025) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2025.03.018 · Cited by 18
“According to previous studies, Bcl-2 and caspase-3 are key markers of cell apoptosis signaling pathways 59,60 .”
Chemogenomics for drug discovery: clinical molecules from open access chemical probes
Quinlan, R. B. A., & Brennan, P. E. (2021) · RSC Chemical Biology · doi:10.1039/d1cb00016k · Cited by 20
Patent landscape of inhibitors and PROTACs of the anti-apoptotic BCL-2 family proteins
Pal, P., Zhang, P., Poddar, S. K., & Zheng, G. (2022) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2022.2116311 · Cited by 19
Viedma‐Rodríguez, R., Baiza-Gutman, L. A., García-Carrancá, A. M., Moreno‐Fierros, L., Salamanca-Gómez, F., & Arenas-Aranda, D. J. (2013) · International Journal of Oncology · doi:10.3892/ijo.2013.2127 · Cited by 18
“We found low expression of BAX, BAK and PUMA pro-apoptotic proteins and high expression of some anti-apoptotic proteins, such as BCL-2 and MCL-1 in BIK siRNA-transfected cells after treatment with TAM, the latter two proteins have been shown to be involved in the prevention of Cyt C release (26,27).”
RetractedInherited Thrombocytopenia Caused by Variants in Crucial Genes for Glycosylation
Marín‐Quilez, A., Díaz‐Ajenjo, L., Buduo, C. A. D., Zamora‐Cánovas, A., Lozano, M. L., Benito, R., González‐Porras, J. R., Balduini, A., Rivera, J., & Bastida, J. M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24065109 · Cited by 17
“Platelet loss of function and death is governed by unclear mechanisms that share some similarity to those used by nucleated cells for programmed cell death [32].”
BackgroundDevelopmental Stage–Specific Manifestations of Absent TPO/c-MPL Signalling in Newborn Mice
Lorenz, V., Ramsey, H. E., Liu, Z.-J., Italiano, J. E., Hoffmeister, K. M., Bihorel, S., Mager, D. E., Hu, Z., Slayton, W. B., Kile, B. T., et al. (2017) · Thrombosis and Haemostasis · doi:10.1160/th17-06-0433 · Cited by 17
The necroptotic cell death pathway operates in megakaryocytes, but not in platelet synthesis
Moujalled, D., Gangatirkar, P., Kauppi, M., Corbin, J. E., Lebois, M., Murphy, J. M., Lalaoui, N., Hildebrand, J. M., Silke, J., Alexander, W. S., et al. (2021) · Cell Death and Disease · doi:10.1038/s41419-021-03418-z · Cited by 17
Targeting the B-cell lymphoma 2 anti-apoptotic proteins for cervical cancer treatment
Rahman, S. F. A., Lian, B. S. X., & Mohana‐Kumaran, N. (2020) · Future Oncology · doi:10.2217/fon-2020-0389 · Cited by 16
Ren, Y., Huang, S.-H., Macedo, A. B., Ward, A. R., Alberto, W. D. C., Klevorn, T., Leyre, L., Copertino, D. C., Mota, T. M., Chan, D., et al. (2021) · Journal of Virology · doi:10.1128/jvi.02425-20 · Cited by 17
Subcutaneous delivery of a dendrimer-BH3 mimetic improves lymphatic uptake and survival in lymphoma
Feeney, O. M., Ardipradja, K., Noi, K. F., Mehta, D. C., Rose, R. D., Yuen, D., Johnston, A. P. R., Kingston, L. P., Ericsson, C., Elmore, C. S., et al. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.05.041 · Cited by 16
Ya, F., Tian, J., Li, Q., Chen, L., Ren, J., Zhao, Y., Wan, J., Ling, W., & Yang, Y. (2018) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.8b03266 · Cited by 16
Adoptive transfer method to study platelet function in mouse models of disease
Bergmeier, W., & Boulaftali, Y. (2014) · Thrombosis Research · doi:10.1016/j.thromres.2014.03.002 · Cited by 16
“Thrombocytopenia in mice can also be induced by chemotherapeutic agents such as 1,4butanediol dimethanesulfonate (Busulfan) [13] or Abt-737, a small molecule inhibitor that targets pro-survival Bcl-2 proteins [14,15].”
BackgroundPhillips, D. C., Xiao, Y., Lam, L., Litvinovich, E. F., Roberts-Rapp, L. A., Souers, A. J., & Leverson, J. D. (2016) · Blood Cancer Journal · doi:10.1038/bcj.2016.12 · Cited by 16
Human thrombopoiesis depends on Protein kinase C /protein kinase C functional couple
Carubbi, C., Masselli, E., Martini, S., Galli, D., Aversa, F., Mirandola, P., Italiano, J. E., Gobbi, G., & Vitale, M. (2016) · Haematologica · doi:10.3324/haematol.2015.137984 · Cited by 16
Kunkalla, K., Liu, Y., Qu, C., Leventaki, V., Agarwal, N. K., Singh, R. R., & Vega, F. (2013) · Annals of Hematology · doi:10.1007/s00277-013-1684-6 · Cited by 15
“Antiapoptotic proteins are key mediators of programmed cell death that are frequently expressed in malignant lymphomas [7].”
Stutz, M. D., Ojaimi, S., Ebert, G., & Pellegrini, M. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01178 · Cited by 15
“Receptor-interacting protein kinase 3 was reported to promote macrophage necrosis and therefore disease progression in a process dependent on BCL-XL (25).”
BackgroundInfluentialReview of the impact of fragment-based drug design on PROTAC degrader discovery
Chen, P., Li, Q., & Lei, X. (2024) · TrAC Trends in Analytical Chemistry · doi:10.1016/j.trac.2024.117539 · Cited by 15
Biomarkers of Response to Venetoclax Therapy in Acute Myeloid Leukemia
Rodríguez‐Medina, C., Stuckey, R., Bilbao, C., & Gómez‐Casares, M. T. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25031421 · Cited by 14
“However, a second BCL-2 inhibitor, ABT-199, was better tolerated than ABT-263 in clinical trials because it does not target Bcl-XL and thus did not reduce platelet survival [18,19].”
BackgroundThalidomide derivatives degrade BCL-2 by reprogramming the binding surface of CRBN
Wang, J., Heinz, M., Han, K., Shah, V. J., Hasselbeck, S., Schwalm, M. P., Rathore, R., Hummer, G., Zhou, J., Đikić, I., et al. (2024) · Cell Reports Physical Science · doi:10.1016/j.xcrp.2024.101960 · Cited by 14
PROteolysis‐Targeting Chimeras (PROTACs) in leukemia: overview and future perspectives
Vicente, A. T. S., & Salvador, J. A. R. (2024) · MedComm · doi:10.1002/mco2.575 · Cited by 14
Anti-apoptotic role of sonic hedgehog on blood platelets
Kumari, S., Chaurasia, S. N., Kumar, K., & Dash, D. (2014) · Thrombosis Research · doi:10.1016/j.thromres.2014.09.022 · Cited by 14
“Pharmacological inhibition of Bcl-xL by ABT-737 leads to apoptosis-like events in blood platelets [10,11] and enhanced clearance of platelets by the reticuloendothelial system [19].”
BackgroundAcute toxicity analysis of Disarib, an inhibitor of BCL2
Sharma, S., Varsha, K. K., Kumari, S., Gopalakrishnan, V., Jose, A. E., Choudhary, B., Mantelingu, K., & Raghavan, S. C. (2020) · Scientific Reports · doi:10.1038/s41598-020-72058-8 · Cited by 14
Pasqua, L. G. D., Abdallah, M. M., Feletti, F., Vairetti, M., & Ferrigno, A. (2024) · Pharmaceuticals · doi:10.3390/ph17040484 · Cited by 15
“This hematological toxicity is a direct consequence of platelet dependence on BCL-XL for survival [38].”
BackgroundInfluentialPlatelet-Derived Microparticles
Cointe, S., Lacroix, R., & Dignat‐George, F. (2017) · Springer eBooks · doi:10.1007/978-3-319-47462-5_28 · Cited by 13
General Aspects of Thrombocytopenia, Platelet Transfusions, and Thrombopoietic Growth Factors
Kuter, D. J. (2013) · Elsevier eBooks · doi:10.1016/b978-1-4557-2296-9.00008-7 · Cited by 13
Bortner, C. D., Oakley, R. H., & Cidlowski, J. A. (2022) · Cell Death Discovery · doi:10.1038/s41420-022-01285-x · Cited by 13
“However, as Bcl-xL was found to be essential for the survival of mature platelets [14, 15], the effectiveness of ABT737 was limited.”
BackgroundElrahman, I. A., Deutsch, V., Pick, M., Kay, S., Neuman, T., Perlman, R., & Ben‐Yehuda, D. (2013) · Cell Death and Disease · doi:10.1038/cddis.2013.454 · Cited by 13
“A number of studies propose that during late megakaryocytic maturation there are relationships between activation of the intrinsic apoptotic pathway and platelet production(6) and the modulation of platelet survival.(7,8) Interestingly, there is a distinct accumulation of caspases in mature MKs and platelets: caspase-…”
BackgroundBiomarkers of Therapeutic Response to BCL2 Antagonists in Cancer
Lam, L. T., Zhang, H., & Chyla, B. (2012) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-012-0003-6 · Cited by 13
Self-citationEvaluation of the Bcl-2 family antagonist ABT-737 in collagen-induced arthritis
Lawlor, K. E., Smith, S. D. G., van Nieuwenhuijze, A. E. M., Huang, D. C. S., & Wicks, I. P. (2011) · Journal of Leukocyte Biology · doi:10.1189/jlb.0311174 · Cited by 13
“ABT-737 causes lymphopenia and transiently depletes platelets in mice [28, 29].”
Background
Metadata
- Authors
- Zhang, H., Nimmer, P. M., Tahir, S. K., Chen, J., Fryer, R. M., Hahn, K. R., Iciek, L. A., Morgan, S. J., Nasarre, M. C., Nelson, R., Preusser, L. C., Reinhart, G. A., Smith, M. L., Rosenberg, S. H., Elmore, S. W., & Tse, C.
- Affiliations
- Abbott (United States) (US)
- Corresponding author
- Elmore, S W
- Tse, C
- Venue
- Cell Death & Differentiation
- Published
- 2007-01-05
- Volume
- 14
- Issue
- 5
- Pages
- 943-951
- ISSN
- 1350-9047 (ISSN-L)
- 1476-5403
- OpenAlex
- W1976197588
- Cited by
- 427
- References
- 32
- Citations by year
- 2026: 12 · 2025: 16 · 2024: 17 · 2023: 20 · 2022: 28 · 2021: 38 · 2020: 31 · 2019: 15 · 2018: 24 · 2017: 27 · 2016: 27 · 2015: 23 · 2014: 27 · 2013: 26 · 2012: 21
- FWCI
- 11.29
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Cell Death and Differentiation (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Hematology › Platelet Disorders and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
- Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
- Keywords
- platelet survival, Bcl-2 family proteins, ABT-737, platelet clearance, caspase-3 activation, cytochrome c release, phosphatidylserine exposure, mitochondrial membrane potential, reticuloendothelial system, hepatic clearance, platelet activation, hemostasis
- MeSH terms
- Animals, Biphenyl Compounds, Blood Platelets, Cell Separation, Cell Survival, Cytoplasmic Granules, Dogs, Dose-Response Relationship, Drug, Exocytosis, Flow Cytometry, Humans, Liver, Male, Nitrophenols, Phosphatidylserines, Piperazines, Platelet Aggregation, Platelet Count, Sulfonamides, Apoptosis, Proto-Oncogene Proteins c-bcl-2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.